Carvedilol (Eucardic - Boehringer Mannheim), a mixed α1- and β-adrenoceptor blocker, has recently been licensed for the treatment of patients with all grades of hypertension. The manufacturer claims that its dual mode of action "extends the scope of β-blocker therapy" and "results in fewer of the unwanted effects typical with standard β-blockers". We examine the claims for carvedilol and consider its place in the management of hypertension.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.